ReviewJournal of leukocyte biology2018
Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD).
Review in Journal of leukocyte biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 44 citations in OpenAlex.
- Eosinophil diversity and function: emerging insights into subtypes and therapeutic targets.Cell death discovery · 2026Review
- Circulating eosinophils in patients with hypereosinophilic syndrome have heterogeneous immunophenotypes.The journal of allergy and clinical immunology. Global · 2026Article
- Spatial Eosinophil Phenotypes as Immunopathogenic Determinants in Inflammatory Diseases.Cells · 2025Review
- The role of eosinophils and their activation state in hypereosinophilia-associated heart disease.Frontiers in immunology · 2025Article
- Utility of eosinophil peroxidase as a biomarker of eosinophilic inflammation in asthma.The Journal of allergy and clinical immunology · 2024Article
- Biologic therapy in rare eosinophil-associated disorders: remaining questions and translational research opportunities.Journal of leukocyte biology · 2024Review
- Mepolizumab has clinical benefits including oral corticosteroid sparing irrespective of baseline EGPA characteristics.ERJ open research · 2024Article
- Article
- Siglecs as potential targets of therapy in human mast cell- and/or eosinophil-associated diseases.Seminars in immunology · 2023Review
- Urine eosinophil-derived neurotoxin: A potential marker of activity in select eosinophilic disorders.Allergy · 2023Article
- IgE Immune Complexes Mitigate Eosinophilic Immune Responses through NLRC4 Inflammasome.Mediators of inflammation · 2023Article
- In Vivo ETosis of Human Eosinophils: The Ultrastructural Signature Captured by TEM in Eosinophilic Diseases.Frontiers in immunology · 2022Article
- NLRC4 Inflammasome-Mediated Regulation of Eosinophilic Functions.Immune network · 2021Article
- Emerging Evidence for Pleiotropism of Eosinophils.International journal of molecular sciences · 2021Review
- Eosinophil Knockout Humans: Uncovering the Role of Eosinophils Through Eosinophil-Directed Biological Therapies.Annual review of immunology · 2021Article
- Assessment of Lung Eosinophils In Situ Using Immunohistological Staining.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Single-Organ and Multisystem Hypereosinophilic Syndrome Patients with Gastrointestinal Manifestations Share Common Characteristics.The journal of allergy and clinical immunology. In practice · 2020Article
- A FACS-based approach to obtain viable eosinophils from human adipose tissue.Scientific reports · 2020Article
- Contributions of Eosinophils to Human Health and Disease.Annual review of pathology · 2020Review
- Fibrinogen Is a Specific Trigger for Cytolytic Eosinophil Degranulation.Journal of immunology (Baltimore, Md. : 1950) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 18 institutions in 6 countries.
Funding
Abstract
Eosinophil-associated diseases (EADs) are rare, heterogeneous disorders characterized by the presence of eosinophils in tissues and/or peripheral blood resulting in immunopathology. The heterogeneity of tissue involvement, lack of sufficient animal models, technical challenges in working with eosinophils, and lack of standardized histopathologic approaches have hampered progress in basic research. Additionally, clinical trials and drug development for rare EADs are limited by the lack of primary and surrogate endpoints, biomarkers, and validated patient-reported outcomes. Researchers with expertise in eosinophil biology and eosinophil-related diseases reviewed the state of current eosinophil research, resources, progress, and unmet needs in the field since the 2012 meeting of the NIH Taskforce on the Research of Eosinophil-Associated Diseases (TREAD). RE-TREAD focused on gaps in basic science, translational, and clinical research on eosinophils and eosinophil-related pathogenesis. Improved recapitulation of human eosinophil biology and pathogenesis in murine models was felt to be of importance. Characterization of eosinophil phenotypes, the role of eosinophil subsets in tissues, identification of biomarkers of eosinophil activation and tissue load, and a better understanding of the role of eosinophils in human disease were prioritized. Finally, an unmet need for tools for use in clinical trials was emphasized. Histopathologic scoring, patient- and clinician-reported outcomes, and appropriate coding were deemed of paramount importance for research collaborations, drug development, and approval by regulatory agencies. Further exploration of the eosinophil genome, epigenome, and proteome was also encouraged. Although progress has been made since 2012, unmet needs in eosinophil research remain a priority.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.